VIVUS (VVUS) Qsymia Continues to See Strong Early Demand
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Price: $0.47 --0%
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Shares of VIVUS Inc. (NASDAQ: VVUS) are fractionally lower Monday despite data showing that recently launched obesity drug Qsymia is posting strong sales momentum.
In its third week, Qsymia prescriptions rose 150 percent sequentially, according to Bloomberg Industries which cited data from Source Healthcare Analytics. 53 percent of Qsymia prescriptions were paid for by commercial insurers, versus 36 percent in week two.
"While it often takes several weeks for data to reflect true demand, payors and patients appear to be adopting Qsymia", the analyst said.
Qsymia has the first-mover advantage in the space but Arena Pharmaceuticals' (NASDAQ: ARNA) Belviq is expected to hit in the fourth quarter.
In its third week, Qsymia prescriptions rose 150 percent sequentially, according to Bloomberg Industries which cited data from Source Healthcare Analytics. 53 percent of Qsymia prescriptions were paid for by commercial insurers, versus 36 percent in week two.
"While it often takes several weeks for data to reflect true demand, payors and patients appear to be adopting Qsymia", the analyst said.
Qsymia has the first-mover advantage in the space but Arena Pharmaceuticals' (NASDAQ: ARNA) Belviq is expected to hit in the fourth quarter.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand
- Deere (DE) PT Lowered to $728 at UBS as Agricultural Machinery Cycle Gets Closer
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
